دورية أكاديمية
Breakthrough infection by hepatitis B virus in a vaccinated blood donor: An emerging threat for transfusion safety in low-endemic countries?
| العنوان: | Breakthrough infection by hepatitis B virus in a vaccinated blood donor: An emerging threat for transfusion safety in low-endemic countries? |
|---|---|
| المؤلفون: | Blanco S; Fundación Banco Central de Sangre, Córdoba, Argentina.; Instituto de Virología, Facultad de Ciencias Médicas, Universidad Nacional de Córdoba, Córdoba, Argentina., Castro GM; Instituto de Virología, Facultad de Ciencias Médicas, Universidad Nacional de Córdoba, Córdoba, Argentina.; Departamento Laboratorio Central, Ministerio de Salud de la Provincia de Córdoba, Córdoba, Argentina., Sicilia PE; Instituto de Virología, Facultad de Ciencias Médicas, Universidad Nacional de Córdoba, Córdoba, Argentina., Carrizo LH; Fundación Banco Central de Sangre, Córdoba, Argentina., Gallego SV; Fundación Banco Central de Sangre, Córdoba, Argentina.; Instituto de Virología, Facultad de Ciencias Médicas, Universidad Nacional de Córdoba, Córdoba, Argentina.; CONICET (Consejo Nacional de Investigaciones Científicas y Técnicas), Buenos Aires, Argentina. |
| المصدر: | Journal of medical virology [J Med Virol] 2024 Feb; Vol. 96 (2), pp. e29463. |
| نوع المنشور: | Case Reports; Journal Article |
| اللغة: | English |
| بيانات الدورية: | Publisher: Wiley-Liss Country of Publication: United States NLM ID: 7705876 Publication Model: Print Cited Medium: Internet ISSN: 1096-9071 (Electronic) Linking ISSN: 01466615 NLM ISO Abbreviation: J Med Virol Subsets: MEDLINE |
| أسماء مطبوعة: | Publication: New York Ny : Wiley-Liss Original Publication: New York, Liss. |
| مواضيع طبية MeSH: | Hepatitis B virus*/genetics , Hepatitis B*/diagnosis , Hepatitis B*/prevention & control , Hepatitis B*/epidemiology, Male ; Humans ; Breakthrough Infections ; Blood Donors ; DNA, Viral/genetics ; Hepatitis B Surface Antigens ; Hepatitis B Core Antigens ; Hepatitis B Antibodies |
| مستخلص: | We present the case of a breakthrough infection by hepatitis B virus (HBV), intending to warn about the challenge that HBV represents for transfusion safety. Virological markers for HBV infection were assayed during a blood donor screening by detection of HBsAg, anti-HBc, and viral nucleic acid (HBV DNA) by a nucleic acid test (NAT). Additionally, samples were analyzed for detection of immunoglobulin M anti-HBc, HBeAg, anti-HBe, and anti-HBs. A first-time donor repeatedly tested positive for HBV DNA by NAT and nonreactive for HBV-serological markers of infection. He stated having completed the anti-HBV vaccination schedule; thus, study of anti-Hbs resulted in reactive at protective level (18 mIU/mL). The donor denied clinical symptoms of hepatitis and remained healthy during the follow-up period. 95 days postdonation, NAT was negative, seroconversion of anti-HBc ab was detected, and a significant increase in anti-HBs concentration was measured (>1000 mIU/mL). This is the first case of HBV-breakthrough infection reported in Argentina and to our knowledge, this potential threat to transfusion safety is novel in an HBV low-endemic region with high coverage of HBV vaccination. The occurrence of breakthrough infections challenges the current protocols for the identification of HBV-infected subjects, could be a source of silent HBV transmission. (© 2024 Wiley Periodicals LLC.) |
| References: | Kuhns MC, McNamara AL, Holzmayer V, Cloherty GA. Molecular and serological characterization of hepatitis B vaccine breakthrough infections in serial samples from two plasma donors. Virol J. 2019;16:43. doi:10.1186/s12985-019-1154-4. Seed CR, Jones NT, Pickworth AM, Graham WR. two cases of asymptomatic HBV “vaccine breakthrough” infection detected in blood donors screened for HBV DNA. Med J Aust. 2012;196(10):651-652. doi:10.5694/mja11.11589. Di Lello FA, Blejer J, Alter A, et al. Hepatitis B surface antibodies seroprevalence among people born before and after implementation of universal HBV vaccination. Vaccine. 2020;38(12):2678-2682. doi:10.1016/j.vaccine.2020.02.014. Castro GM, Sosa MJ, Sicilia PE, et al. Acute and chronic HBV infection in central Argentina: high frequency of sub-genotype F1b, low detection of clinically relevant mutations and first evidence of HDV. Front Med. 2023;9:1057194. doi:10.3389/fmed.2022.1057194. Blanco S, Balangero MC, Valle MC, Montini OL, Carrizo LH, Gallego SV. Usefulness of nucleic acid testing to reduce risk of hepatitis B virus transfusion-transmitted infection in Argentina: high rate of recent infections. Transfusion. 2017;57(3pt2):816-822. doi:10.1111/trf.13946. Pisano MB, Blanco S, Carrizo H, Ré VE, Gallego S. Hepatitis B virus infection in blood donors in Argentina: prevalence of infection, genotype distribution and frequency of occult HBV infection. Arch Virol. 2016;161(10):2813-2817. doi:10.1007/s00705-016-2960-2. Ministerio de Salud. Presidencia de la Nación. Hepatitis B. Calendario Nacional de Vacunación. 2000. Accessed January 3, 2024. https://www.argentina.gob.ar/salud/vacunas/hepatitisb#:~:text=Desde%202012%20es%20obligatoria%20y,mes%20de%20la%201er%20dosis. Organización Panamericana de la Salud. La Argentina se posiciona con altos niveles de cobertura de vacunación en la región. 2011. Accessed January 3, 2024. https://www.paho.org/es/noticias/18-4-2011-argentina-se-posiciona-con-altos-niveles-cobertura-vacunacion-region. Ministerio de Salud. Presidencia de la Nación. III Informe de cobertura de vacunación en Argentina 2022. 2023. Accessed January 3, 2024. https://bancos.salud.gob.ar/recurso/iii-informe-de-coberturas-de-vacunacion-en-argentina-2022. Dirección de Respuesta al VIH, ITS, Hepatitis virales y tuberculosis. Ministerio de Salud. Presidencia de la Nación. Boletín N°4 Hepatitis Virales en Argentina. Diciembre de 2022. Boletín N°5 Hepatitis Virales en Argentina. 2023. Accessed October 17, 2023. https://bancos.salud.gob.ar/recurso/boletin-de-hepatitis-virales-en-la-argentina-ndeg-4-dic-2022. Anastasiou OE, Widera M, Korth J, et al. Clinical patterns associated with the concurrent detection of anti-HBs and HBV DNA. J Med Virol. 2018;90:282-290. doi:10.1002/jmv.24942. Hoshi Y, Hasegawa T, Yamagishi N, et al. Optimal titer of anti-HBs in blood components derived from donors with anti-HBc. Transfusion. 2019;59:2602-2611. doi:10.1111/trf.15393. Levicnik-Stezinar S, Rahne-Potokar U, Candotti D, Lelie N, Allain JP. AntiHBs positive occult hepatitis B virus carrier blood infectious in two transfusion recipients. J Hepatol. 2008;48:1022-1025. Deng X, Guo X, Gu H, et al. Anti-HBc-nonreactive occult hepatitis B infections with HBV genotypes B and C in vaccinated immunocompetent adult. J Viral Hepatitis. 2022;29:958-967. doi:10.1111/jvh.13733. Alawi FB, Robertson PW, LePage AK, Jayamaha J, Baleriola C, Rawlinson WD. The reliability of HBV core antibody in serological screening for hepatitis B virus. Pathology. 2013;45(5):501-505. doi:10.1097/PAT.0b13e3283631cf9. |
| معلومات مُعتمدة: | Fundación Banco Central de Sangre |
| فهرسة مساهمة: | Keywords: argentina; blood donors; hepatitis B virus; hepatitis B virus genotypes; transfusion transmitted infection; vaccine breakthrough |
| المشرفين على المادة: | 0 (DNA, Viral) 0 (Hepatitis B Surface Antigens) 0 (Hepatitis B Core Antigens) 0 (Hepatitis B Antibodies) |
| تواريخ الأحداث: | Date Created: 20240212 Date Completed: 20240214 Latest Revision: 20240214 |
| رمز التحديث: | 20240214 |
| DOI: | 10.1002/jmv.29463 |
| PMID: | 38345135 |
| قاعدة البيانات: | MEDLINE |
Full Text Finder كن أول من يترك تعليقا!